Telaah pustaka farmakogenetik Antiemetik Antagonis Reseptor 5-hidroksitriptamin 3 dalam onkologi Parmacogenetic of 5 Hydroxytriptamine 3B IN oncology- a review
| Main Author: | Dyah Aryani, Perwitasari |
|---|---|
| Format: | Article PeerReviewed Book Lainnya |
| Bahasa: | eng |
| Terbitan: |
, 2008
|
| Subjects: | |
| Online Access: |
http://repo.unand.ac.id/1960/1/Jurnal_03.pdf http://repo.unand.ac.id/1960/2/Jurnal_03.ps http://repo.unand.ac.id/1960/ |
Daftar Isi:
- Nausea and vorniting are the most distressful side effects of cytotoxic drugs in cancer patiens. Anti emetics, such as 5 Hydroxytriptamine 3 reseptor antagonist (5 HT3), dopamine antagonist and neurokinin 1 antagonist are commonly used to reduce these side effect. However, the efficacy of current anticmetics about 70%-80% in cancer patiens treated with hight emetogenic cytotoxic drugs. One of the potential factors explaining this suboptimal response is variability in genes encoding enzymes anda proteins which play a role in metabolism, transport and receptors to anti-emetic drugs, beside other risk factors. This review presents the generic variation of the 5 HT3 reseptor, CYP2D6 anda ATP Binding Casette subfamily B member 1 (ABCB1). Moreover, pharmacogenetic studies exploring associations between genetic variation related to these anti-emetics and offycacy are reviewed. Keyword: anti-emetics, pharmaeogenetics, cancer